GLP-1: WHO Guidelines, 1 Billion People, 3 Industries
Science published an editorial on 3 September 2026 by Luc Hagenaars of Amsterdam UMC and Laura Schmidt of the University of California San Francisco, about what happens around the GLP-1 class once it becomes enormous.
It is a policy argument rather than a study, and it is worth reading for one paragraph in particular: the list of who is now competing for position around these medicines.
A framing note. This is an opinion piece in a scientific journal, not new data, and we are reporting it as such. Peptra Labs supplies research materials on a research use only basis and nothing below is guidance about human use.
What the GLP-1 editorial says
The authors open by observing how thoroughly these pharmacotherapies have taken over public discussion of obesity. They describe an avalanche of scientific papers, news articles and social media posts debating efficacy, affordability and appropriateness, and not only for obesity: they list skin disease, erectile dysfunction, pregnancy and addiction as areas where the debate has spread.
Against that noise, they set the World Health Organization’s guideline.
WHO issued its global guideline on the use of GLP-1 medicines in treating obesity on 1 December 2025. The editorial describes it as the first ever of its kind, alongside a commitment to develop a global framework ensuring what the authors quote as “fair access” for the one billion people affected worldwide.
They also note something the coverage of that guideline mostly skipped. It advocates for what they quote as “robust population-level policies” to address the root causes of obesity in unhealthy food environments. The guideline is not only about prescribing.
The three industries around GLP-1
The core of the editorial is a single observation about timing.
WHO’s recommendations, the authors write, unfold at a time of competitive pressure among three groups at once.
| Group | What the authors describe |
|---|---|
| Pharmaceutical companies | competing among themselves in the same market |
| Food companies | vying for the GLP-1 market segment |
| Wellness companies | promoting supplements and telemedicine programmes for what is being billed as a GLP-1 lifestyle |
Their conclusion is that this commercial environment is ripe for unintended consequences that work against fair access.
The third row is the one worth sitting with. A guideline aimed at a billion people arrives into a market where an entire adjacent industry has formed around the idea of GLP-1 rather than around the medicines themselves.
Where a research supplier sits in the GLP-1 picture
We are not a wellness company and we do not sell supplements or telemedicine, but we are adjacent enough to the third row that pretending otherwise would be dishonest.
Peptra Labs supplies characterised reference material to laboratories. That is a narrower business than the one the editorial describes, and the distinction only holds if it is actually maintained. Our own writing on the risk profile of research peptides and on where the research use boundary sits exists because the boundary is easy to state and easy to erode.
Two days ago we covered a case report of a product bought online and used by someone at home, which is what the erosion looks like in a single patient. This editorial is the same GLP-1 problem viewed from policy altitude.
What the editorial does not do
It is two pages in a news and commentary section, and it makes no attempt at data.
There is no quantification of the wellness market, no estimate of how much fair access is actually compromised, and no evidence offered that the three commercial pressures interact in the way proposed. Those are reasonable omissions for the format and they are also the reason this should be read as an argument rather than a finding.
The authors are a public health academic and a health policy academic, which is the relevant expertise for the claim being made and is not the expertise that would settle it empirically.
Access, and what the GLP-1 evidence actually supports
The fair access argument only bites if the medicines do what the guideline says, and there the picture is more measured than the discourse.
Earlier this week we covered a systematic review that placed the numbers side by side in Annals of Internal Medicine, across 38 trials and 25,816 participants. The effect sizes are large. The authors of that review also stated that heterogeneity prevented them from pooling, so the table is not a ranking.
That is the honest version of the evidence a global access framework would be distributing: substantial, real, and less precisely comparable between agents than the public conversation assumes.
The gap between those two descriptions is roughly the gap the editorial is complaining about.
What it means for the catalogue
The regulatory environment around the GLP-1 class is tightening in several places at once, and a supplier is better off tracking it than ignoring it.
We covered the 503A bulks list vote earlier this year, and the compounding disputes have continued through the courts since. This editorial adds the global layer: a WHO framework in preparation, aimed at distribution and access rather than at compounding or supply.
Tirzepatide sits inside that framework as an approved medicine in most large markets. Retatrutide sits outside it entirely, because it is not approved anywhere, which means no access framework covers it and no guideline mentions it.
That asymmetry is worth keeping in view. Policy attention follows approval, and the compounds furthest from approval are the ones with the least oversight attached to them.
References
- Hagenaars LL, Schmidt LA. (Un)intended consequences of mass-prescribing GLP-1s. Science, 3 September 2026, 393(6815):953. doi 10.1126/science.ael8715
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. 1 December 2025
- Moiz A, Filion KB, Samuels AE, et al. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review. Annals of Internal Medicine, 1 September 2026
- Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus, 26 August 2026, 18(8):e115260
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
